<unk>  (trade name Erivedge ) is a drug for the treatment of basal-cell carcinoma (BCC). The approval of<unk>  on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval. The drug is also undergoing clinical trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma . The drug was developed by the biotechnology/pharmaceutical company Genentech.
Vismodegib
Etalocib
Duvelisib
Selpercatinib
Enasidenib
Idelalisib
Ivosidenib
Brigatinib